Levetiracetam: 6 agencies, 2006–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil) has been easier on levetiracetam than on its own caseload: it refused 1 of 5 decisive submissions here (20%), against a base rate of 44% across everything it has assessed.
The file has been open for more than a decade: 19 years separate the first record, 19 Jul 2006 at HAS (France), from the most recent, 16 Jul 2025 at HAS (France).
PHARMAC (New Zealand) changed its position: not recommended on 8 Nov 2012, recommended by 15 Aug 2022, after a resubmission.
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
HAS (France) was first to assess levetiracetam, on 19 Jul 2006; CONITEC (Brazil) did not open a file until 22 Feb 2017 — an unusually long tail of 10.6 years between the earliest and latest system to look at it.
The record arrives in waves: 11 separate years each carry two or more decisions, spread across 15 years in total.
4 of the 6 agencies here assessed levetiracetam more than once, HAS (France) most often at 21 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for levetiracetam.
The full ledger for levetiracetam reads 23 recommended, 6 other, 3 not recommended and 1 not assessed.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 16 Jul 2025 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| PHARMAC (New Zealand) | 15 Aug 2022 | Seizure control ,palliative care | PTAC advice: Medium · decision reached | source |
| CONITEC (Brazil) | 29 Sep 2021 | Tratamento adjuvante para epilepsia. | incorporated into SUS | source |
| AWMSG (Wales) | 8 May 2013 | Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 year… | outside AWMSG criteria | source |
| TLV (Sweden) | 6 Sep 2011 | Levetiracetam Desitin ingår i högkostnadsskyddet | general subsidy | source |
28 further decisions for levetiracetam, across 5 agencies, are not shown here. They link to 17 further source documents.
Related molecules
- cannabidiol — same ATC class N03A — Antiepileptics
- perampanel — same ATC class N03A — Antiepileptics
- lacosamide — same ATC class N03A — Antiepileptics
- brivaracetam — same ATC class N03A — Antiepileptics
- zonisamide — same ATC class N03A — Antiepileptics
- rufinamide — same ATC class N03A — Antiepileptics
Coverage: 33 decisions for levetiracetam from 6 agencies, 2006 to 2025. Data to 7 Sep 2026. ATC class N03A — Antiepileptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.